Update and latest advances in antiretroviral therapy
L Menéndez-Arias, R Delgado - Trends in pharmacological sciences, 2022 - cell.com
Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …
1) infection has reached pandemic proportions. Forty years later, research has led to the …
Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART
S Zicari, L Sessa, N Cotugno, A Ruggiero, E Morrocchi… - Viruses, 2019 - mdpi.com
Despite effective antiretroviral therapy (ART), people living with HIV (PLWH) still present
persistent chronic immune activation and inflammation. This condition is the result of several …
persistent chronic immune activation and inflammation. This condition is the result of several …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label …
ET Overton, G Richmond, G Rizzardini, H Jaeger… - The Lancet, 2020 - thelancet.com
Background Phase 3 clinical studies showed non-inferiority of long-acting intramuscular
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection
C Orkin, K Arasteh… - … England Journal of …, 2020 - Mass Medical Soc
Background Long-acting injectable regimens may simplify therapy for patients with human
immunodeficiency virus type 1 (HIV-1) infection. Methods We conducted a phase 3 …
immunodeficiency virus type 1 (HIV-1) infection. Methods We conducted a phase 3 …
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for …
J Van Wyk, F Ajana, F Bisshop, S De Wit… - Clinical Infectious …, 2020 - academic.oup.com
Background The 2-drug regimen dolutegravir (DTG)+ lamivudine (3TC) is indicated for
treatment-naive adults with human immunodeficiency virus type 1 (HIV-1). We present …
treatment-naive adults with human immunodeficiency virus type 1 (HIV-1). We present …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA Panel
MS Saag, RT Gandhi, JF Hoy, RJ Landovitz… - Jama, 2020 - jamanetwork.com
Importance Data on the use of antiretroviral drugs, including new drugs and formulations, for
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …
Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment–naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori… - JAIDS Journal of …, 2020 - journals.lww.com
Background: The 2-drug regimen dolutegravir+ lamivudine was noninferior to dolutegravir+
tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA< 50 copies/mL in …
tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA< 50 copies/mL in …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
C Orkin, S Oka, P Philibert, C Brinson, A Bassa… - The Lancet …, 2021 - thelancet.com
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase …
C Orkin, EB Morell, DHS Tan, H Katner, HJ Stellbrink… - The lancet HIV, 2021 - thelancet.com
Background Previous work established non-inferiority of switching participants who were
virologically suppressed from daily oral standard of care to monthly long-acting …
virologically suppressed from daily oral standard of care to monthly long-acting …
Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic …
O Osiyemi, S De Wit, F Ajana, F Bisshop… - Clinical Infectious …, 2022 - academic.oup.com
Background Switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing
tenofovir alafenamide (TAF)–based regimens for maintaining virologic suppression at week …
tenofovir alafenamide (TAF)–based regimens for maintaining virologic suppression at week …